Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaxfectin-formulated H5N1 DNA vaccine
- Development stage
- Unknown
- Lead developer
- Vical
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Vaxfectin-formulated H5N1 DNA vaccine is an investigational vaccine candidate developed by Vical Incorporated for the prevention of infection by the H5N1 subtype of Influenza A virus (avian influenza). The vaccine utilizes a DNA plasmid (VCL-A01) encoding the hemagglutinin (HA) protein of the H5N1 virus, which, upon intramuscular injection, is taken up by host cells to induce the expression of the viral antigen. This process triggers both humoral and cellular immune responses, including the production of neutralizing antibodies and the activation of T cells. To enhance immunogenicity, the plasmid is formulated with Vaxfectin, a proprietary cationic lipid-based adjuvant system consisting of GAP-DMORIE and DPyPE. Vaxfectin facilitates the delivery of the DNA into cells and acts as a potent adjuvant to boost the magnitude and breadth of the immune response. The vaccine reached Phase 2 clinical trials, demonstrating safety and the ability to elicit protective antibody titers in healthy volunteers.
- Other names
- Vaxfectin-adjuvanted H5N1 DNA vaccineVical H5N1 DNA vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Vaxfectin-formulated H5N1 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxfectin-formulated H5N1 DNA vaccine.